Imperial College London

DrLucaMagnani

Faculty of MedicineDepartment of Surgery & Cancer

Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2808l.magnani CV

 
 
//

Location

 

140ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inbook{Magnani:2015:10.1016/B978-0-12-801899-6.00023-1,
author = {Magnani, L and Louloupi, A and Zwart, W},
booktitle = {Epigenetic Biomarkers and Diagnostics},
doi = {10.1016/B978-0-12-801899-6.00023-1},
pages = {467--477},
title = {Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis},
url = {http://dx.doi.org/10.1016/B978-0-12-801899-6.00023-1},
year = {2015}
}

RIS format (EndNote, RefMan)

TY  - CHAP
AB - © 2016 Elsevier Inc. All rights reserved. Epigenetic regulation plays a key role in normal physiology and disease. In breast cancer, multiple epigenetic regulators have been found to be causally involved in tumorigenesis and treatment resistance. Since treatment resistance in breast cancer is commonly observed, epigenetic modifiers may represent promising targets for pharmaceutical intervention. Multiple epigenetic modifiers are currently being targeted in clinical trials with varying success rates. Yet, biological roles of epigenetic modifiers are complex and lack tissue specificity, which may diminish any therapeutic window. Is epigenetic profiling the "new black" of biomarker discovery in breast cancer? and would epigenetic drugs yield the new "silver bullet" in breast cancer treatment, or are we dealing with a "red herring"?
AU - Magnani,L
AU - Louloupi,A
AU - Zwart,W
DO - 10.1016/B978-0-12-801899-6.00023-1
EP - 477
PY - 2015///
SN - 9780128018996
SP - 467
TI - Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis
T1 - Epigenetic Biomarkers and Diagnostics
UR - http://dx.doi.org/10.1016/B978-0-12-801899-6.00023-1
ER -